Structure-based drug discovery and design for novel small molecular inhibitors of Sphingomyelin synt

来源 :全国药物化学学术会议暨第四届中英药物化学学术会议 | 被引量 : 0次 | 上传用户:qmdx521
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Aim To discover novel small molecular inhibitors of sphingomyelin synthase(SMS)as a tool to study the biological function of sphingomyelin synthase and as a lead compound for new preventive and therapeutic drugs of atherosclerosis(AS)and metabolic Syndrome.
其他文献
会议
A novel organic-inorganic hybrids,the so-called cerasomes has been synthesized by combination of sol-gel reaction and self-assembly of a molecular which is analogous to lipids.Firstly,the cerasome for
阿尔茨海默症(Alzheimer’s Disease,AD)又称早老性痴呆,是一种神经退行性疾病1,主要表现为中枢神经系统的退化,神经纤维缠结和老年斑的病理特征。
乳香酸类化合物11-氧代-β-乳香酸乙酸酯(Acetyl 11-keto-β-boswellic acid,AKBA)是一种乌苏烷型的五环三萜类化合物,主要来源于植物卡氏乳香(Boswellia carteri)的胶状树脂,含量约为3.7%[1],具有抗炎、抗肿瘤等多种生物活性.
会议
SL-01,dodecyl-3-((1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamoyl)pyrazine-2-carboxylate,is an oral gemcitabine derivative synthe
目的 阿尔茨海默病(Alzheimer’s disease,AD)是一种常见的中枢神经系统退行性疾病,临床表现为记忆力下降、社交能力出现障碍以及日常自理能力丧失等。
Activation of the phosphatidylinositol 3-kinase α(PI3Kα)is commonly observed in human cancer and is critical for tumour progression,which has made PI3Kα an attractive target for anticancer drug discov